Press Releases

 
Press Releases
  Date Title View
Mar 22, 2017
Board Recommends that Innoviva Shareholders Support the Company's Strategy and Board, Which has Delivered Strong Returns Recommends Shareholders Vote "FOR" All of Innoviva's Highly Qualified Directors on the WHITE Proxy Card BRISBANE, Calif.--(BUSINESS WIRE)-- Innovi...
Mar 13, 2017
BRISBANE, Calif.--(BUSINESS WIRE)-- Innoviva, Inc. (the "Company" or "Innoviva") (NASDAQ: INVA) today issued the following statement. Innoviva has a track record of having a robust and continuing dialogue with its shareholders. On the date of the nomination deadline, Saris...
Mar 7, 2017
Current Board's Strategic Plan has Produced Increased Royalty Revenue, Reduced Operating Expenses and Increased Net Income While Growing Stockholder Returns Sarissa Has Nominated a Slate to Replace a Majority of the Board and Has Provided No Rationale for its Actions nor Proposed a New Strategic ...
Feb 28, 2017
BRISBANE, Calif.--(BUSINESS WIRE)-- Innoviva, Inc. (NASDAQ: INVA) announced today that Michael W. Aguiar, Innoviva's President and Chief Executive Officer will present at the 2017 Cowen Health Care Conference in Boston on March 7 at 9:20 a.m. EST. A live webcast of the presentation can be...
Feb 23, 2017
LONDON & BRISBANE, Calif.--(BUSINESS WIRE)-- GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced positive headline results from a non-inferiority lung function study, which demonstrated that patients with well-controlled asthma were able to switch to the once-daily Relvar® E...
Feb 9, 2017
2016 royalties earned up 119% vs. 2015 Royalties earned in Q4 2016 of $46.8 million, up 80% from Q4 2015 Net income for Q4 2016 of $25.5 million, or $0.24 per share, and adjusted earnings per share of $0.26 per share Announced a new $150 million ...
Feb 2, 2017
BRISBANE, Calif.--(BUSINESS WIRE)-- Innoviva, Inc. (NASDAQ: INVA) announced today that it will report financial results for the fourth quarter and full year ended December 31, 2016 after market close on Thursday, February 9, 2017. Following the earnings release, Innoviva management will host a webcast and confere...
Dec 19, 2016
LONDON & BRISBANE, Calif.--(BUSINESS WIRE)-- GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced the start of a phase III study investigating the effects of once-daily closed triple combination therapy fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) when compared to ther...
Dec 2, 2016
LONDON & BRISBANE, Calif.--(BUSINESS WIRE)-- GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced the filing by GSK of a regulatory submission with the European Medicines Agency for once-daily, closed triple combination therapy fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/...
Dec 2, 2016
LONDON & BRISBANE, Calif.--(BUSINESS WIRE)-- GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Relvar® Ellipta® (fluticasone furoate / vilanterol 100/25 mcg) for the relief of various symptom...
1
...
NextLast
= add release to Briefcase

Innoviva NASDAQ: INVA

$12.91 0.05 (0.39%) 03/23/17 4:00 PM ET Refresh Quote

Data provided by Nasdaq.
Minimum 15 minutes delayed.

Contact

Innoviva Investor Relations & Media
650.238.9640

For business development inquiries,
please contact bd@inva.com.